Acinetobacter baumannii Resistant to Colistin With Impaired Virulence: A Case Report From France

TLDR: The clinical case of a French patient colonized with an A. baumannii colistin-resistant isolate aftercolistin therapy without clinical signs of infection is reported.

Abstract: To the Editor—In an article recently published in the Journal, Lopez-Rojas et al [1] demonstrated that an in vitro mutant of Acinetobacter baumannii resistant to colistin had reduced in vivo fitness and decreased virulence, in terms of both mortality and survival, in a mouse model of peritoneal sepsis. They suggest that the lower in vivo bacterial fitness and decreased virulence of this mutant may explain the low incidence of colistin resistance in the clinical setting. We report herein the clinical case of a French patient colonized with an A. baumannii colistin-resistant isolate after colistin therapy without clinical signs of infection. A 58-year-old patient presented with an influenzalike illness on 16 December 2010 and was treated at home with ampicillin-clavulanic acid. On day 3, he was admitted at Salon de Provence hospital for dyspnea, fever, and right lobar pneumonia on chest x-ray. On day 7, the patient required mechanical ventilation after endotracheal intubation for acute respiratory failure. Antibiotherapy was switched to piperacillin-tazobactam and spiramycin. A bronchoalveolar lavage (BAL) sampled at that time was sterile, and influenza virus detection was negative. Treatment was switched to imipenem-amikacin on day 15 for acute respiratory distress syndrome and septic shock. On day 19, extracorporeal membrane oxy-genation (ECMO) was started for re-fractory hypoxemia, and the patient was referred to an intensive care unit (ICU) in Marseille. On day 21, a colistin-susceptible A. baumannii isolate was recovered from BAL, as well as from 3 blood cultures. Treatment was switched to intravenous colistin and rifampin. ECMO was weaned and sedation was stopped on day 27. Colistin and rifampin were stopped on day 35 but a treatment using imipenem-amikacin-colistin was started on day 37 for a new septic shock episode and stopped on day 41, based on negative BAL and blood cultures. While respiratory status improved, tracheal colonization with colistin-resistant A. baumannii was detected from day 50 to day 60 on biweekly endotracheal aspirate cultures. No clinical sign of infection was present during this period. Asymptomatic bacteri-uria to colistin-sensitive A. baumannii was also present by day 50 and was treated with bladder instillations of colistin from day 57. Treatment was stopped on day 67 when colistin-resistant A. baumannii was isolated from urine samples. The patient was discharged alive from the ICU on day 70. Our case report confirms that colistin-resistant A. baumannii strains may be selected in vivo by the use of colistin but that colistin-resistant strains may be …